甲磺酸阿帕替尼治疗转移性结直肠癌的临床观察

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (12): 1802-1806.

甲磺酸阿帕替尼治疗转移性结直肠癌的临床观察

陈竹¹, 刘艳¹, 高丽花¹, 陈不尤², 唐爱华³, 刘军^1*

南通大学附属医院 1.肿瘤化疗科; 2.肿瘤放疗科; 3.儿内科,江苏南通 226001

收稿日期:2020-09-09 修回日期:2020-12-20 发布日期:2021-12-03
通讯作者: *liujun11301@hotmail.com
基金资助:
南通市科技计划项目(MS12017017-6)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer

CHEN Zhu¹, LIU Yan¹, GAO Li-hua¹, CHEN Bu-you², TANG Ai-hua³, LIU Jun^1*

1. Department of Chemotherapy; 2. Department of Radiotherapy; 3. Department of Pediatrics,the Affiliated Hospital of Nantong University, Nantong 226001, China

Received:2020-09-09 Revised:2020-12-20 Published:2021-12-03
Contact: *liujun11301@hotmail.com

摘要/Abstract

摘要： 目的评价含甲磺酸阿帕替尼方案治疗转移性结直肠癌(mCRC)的疗效和安全性。方法回顾性分析65例含甲磺酸阿帕替尼方案治疗的mCRC患者临床资料,评估影响患者近期有效率、无进展生存时间(PFS)和不良反应等因素。结果 63例可评估疗效患者疾病控制率为69.9%。一线、二线和三线及以上治疗患者的中位PFS分别为9.3个月、5.8个月和3.3个月(P＜0.001)。三线及以上治疗患者中阿帕替尼组和阿帕替尼联合化疗组PFS分别为2.9个月和3.3个月。肝转移患者治疗前后血清胆碱酯酶和白蛋白浓度无明显差异。不良反应主要为1～2级高血压、蛋白尿、骨髓抑制和手足综合征。结论阿帕替尼是mCRC的有效治疗方案,对肝脏储备功能影响小,毒性可控。

关键词: 肠道肿瘤, 甲磺酸阿帕替尼, 临床疗效, 安全性

Abstract: Objective To evaluate the efficacy and safety of apatinib in the treatment of metastatic colorectal cancer (mCRC). Methods Sixty-five patients with mCRC treated with apatinib were enrolled in this study for retrospective analysis. The factors affecting the recent effective, progression-free survival (PFS) and adverse reactions were evaluated. Results The disease control rate in 63 evaluable patients was 69.9%. The median PFS for patients received first-line, second-line, and third-line and above apatinib treatment were 9.3 months, 5.8 months, and 3.3 months, respectively(P＜0.001). The PFS in the apatinib group and the apatinib/chemotherapy combination group in the third-line and above treatment were 2.9 months and 3.3 months, respectively. There was no significant difference in serum cholinesterase and albumin concentrations between patients with liver metastasis before and after treatment. Adverse reactions were mainly grade 1 to 2 hypertension, proteinuria, myelosuppression and hand-foot syndrome. Conclusions Apatinib is an effective treatment with controllable toxicity for mCRC, which has mild adverse effect on liver reserve function.

Key words: intestinal neoplasms, apatinib, clinical efficacy, safety

中图分类号:

陈竹, 刘艳, 高丽花, 陈不尤, 唐爱华, 刘军. 甲磺酸阿帕替尼治疗转移性结直肠癌的临床观察[J]. 基础医学与临床, 2021, 41(12): 1802-1806.

CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun. Clinical observation of apatinib in the treatment of metastatic colorectal cancer[J]. Basic & Clinical Medicine, 2021, 41(12): 1802-1806.

参考文献

[1]郑荣寿, 孙可欣, 张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41: 19-28.
[2]Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144: 646-674.
[3]Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. JAMA, 2018, 319: 2486-2496.
[4]Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015, 16: 619-629.
[5]Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78: 747-758.
[6]Zhou K, Zhang JW, Wang QZ, et al. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice[J]. Acta Pharmacol Sin, 2019, 40: 556-562.
[7]殷亮, 王荩, 黄凤昌,等. 甲磺酸阿帕替尼对结肠癌HCT-116细胞增殖的抑制作用及其机制[J]. 南方医科大学学报, 2017, 37: 367-372.
[8]Zhu JY, Yang X, Chen Y, et al. Curcumin suppresses lung cancer stem cells via inhibiting Wnt/beta-catenin and sonic Hedgehog pathways[J]. Phytother Res, 2017, 31: 680-688.
[9]Liao X, Li H, Liu Z, et al. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine (Baltimore), 2018, 97: e13635. doi:10.1097/MD.0000000000013635.
[10]Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study[J]. J Clin Oncol, 2004, 22: 229-237.
[11]Tabernero J, Van CE, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leuco-vorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial[J]. Eur J Cancer, 2014, 50: 320-331.
[12]Xin M, Xie Q, Ma L, et al. Synergistic anti-tumour effects of Clostridium butyricum in combination with apatinib in CT26 colorectal tumour-bearing mice[J]. Anticancer Drugs, 2019, 30: 991-997.
[13]王珊珊, 汪海岩, 武斌, 等. 甲磺酸阿帕替尼在多线治疗失败的晚期结肠癌中的近期临床疗效与安全性观察[J]. 临床肿瘤学杂志, 2018, 23: 453-457.
[14]Gou M, Si H, Zhang Y, et al. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study[J]. Sci Rep, 2018, 8: 4602. doi: 10.1038/s41598-018-22302-z.
[15]Chen X, Qiu T, Zhu Y, et al. A single-arm, phase II study of apatinib in refractory metastatic colorectal cancer[J]. Oncologist, 2019, 24: 883-e407. doi: 10.1038/s41598-018-22302-z.